West Pharmaceutical stock holds Moderate Buy rating as Annex 1 work shapes outlook

Published on 09/19/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock carries a Moderate Buy consensus rating with a price target of USD 379.08 as of September 19, 2026. Recent commentary highlights Annex 1 compliance investments and risks from cyber disruption and cost inflation for West Vantage.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical Services stock (ISIN US9523901012) remains supported by a Moderate Buy consensus and a stated average analyst price target of USD 379.08 as of September 19, 2026, according to MarketBeat.

Analyst consensus and valuation focus

According to MarketBeat on September 19, 2026, eleven investment analysts currently rate West Pharmaceutical stock Buy and three assign a Hold rating, resulting in a consensus recommendation classified as Moderate Buy.

The same analyst overview from MarketBeat states that the consensus price target for West Pharmaceutical Services stands at USD 379.08, offering investors a concrete benchmark for valuation discussions relative to the current share price on the New York Stock Exchange.

Annex 1 compliance and operational risks

A recent qualitative analysis from Simply Wall St on September 19, 2026 highlights that Annex 1-related compliance upgrades at West Pharmaceutical Services are changing the companys investment narrative by potentially supporting revenue and margin resilience.

As Simply Wall St reports, recent performance has been pressured by weaker results in the West Vantage segment, which have been linked to both a cyber incident and tariff-related cost inflation, signalling that the company faces tangible operational risks alongside its investment in regulatory compliance.

Stock perspective and market data

On the market side, West Pharmaceutical Services shares trade on the New York Stock Exchange in USD; the consensus price target of USD 379.08 cited by MarketBeat as of September 19, 2026 provides a reference point against which investors can compare the latest closing price and evaluate upside potential.